US and South Korean microbiome CDMO partnership to build US facility

Date Published04/12/2022
Author NameBy Jane Byrne
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name List Biotherapeutics, Inc.,
Parent companyList Biological Laboratories, Inc.
Type of work Manufacturing
If manufacturing, is the company a contract manufacturer?Yes
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):201
What product(s) and/or service(s) were outsourced domestically?Manufacturing
Year reshoring announced:2022
Year reshoring implemented or to be implemented:2023
Domestically, the work will be done:In-house
Capital investment ($):125
Country(ies) from which reshored:Korea, Republic of
City reshored to:Fishers
State(s) reshored to:IN
If relevant, work nearshored to:-
Product(s) reshoredMicrobiome anticancer drug
What domestic positive factors made reshoring more attractive?Eco-system synergies, Other, US industry trend to contract manufacturing
Find Reshoring Articles